SPARC announces submission of IND Application for SBO-154 to USFDA

The IND application supports the next phase of development of SBO-154

SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP

SPARC to receive 55% equity in Tiller Therapeutics

SPARC announces results from planned interim analysis of PROSEEK Study

SPARC to present clinical data on vodobatinib

Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML

SPARC partners with Visiox for ophthalmic drugs

SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox

SPARC to licence Biomodifying’s IP

SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP

SPARC announces positive results from Phase 3 trial of PDP-716

The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day

KBR and HJF bags contract to aid military neuroscience research

KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE

India’s Covid success story hailed the world over as a role model in Crisis Management, says Dr. Singh

India's strategy against Covid was more effective than any other countries in the world

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021